文献速递外周动脉疾病

ZILVERPASS研究:ZILVER PTX支架与旁路手术治疗股腘动脉病变的对比

ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
PubMed 文献 · J Endovasc Ther · 2020-01-30

ZILVERPASS研究是一项多中心前瞻性随机对照试验,比较ZILVER PTX紫杉醇洗脱支架与外科旁路术治疗症状性TASC C和D股腘动脉病变的12个月结果。共纳入220例患者,主要终点为12个月一期通畅率。结果显示支架组与旁路组通畅率非劣效,且支架组并发症率更低、手术时间和住院时间更短。

要点

  • ZILVER PTX支架治疗TASC C/D股腘动脉病变12个月一期通畅率非劣效于旁路手术。
  • 支架组30天并发症率显著低于旁路组(4.4% vs 11.3%)。
  • 支架组手术时间和住院时间均显著短于旁路组。

核心结论

  • 对于长段TASC C和D股腘动脉病变,紫杉醇洗脱支架可能成为推荐的治疗选择,因其通畅率非劣效、并发症率更低且手术时间和住院时间更短。

研究设计与样本

  • 多中心、前瞻性、随机对照试验,纳入220例症状性TASC C和D股腘动脉病变患者,随机分为ZILVER PTX支架组(113例)和旁路手术组(107例)。

主要发现

  • 12个月一期通畅率支架组为74.5%(95%CI 66.3%至82.7%),旁路组为72.5%(95%CI 63.7%至81.3%),p=0.998。
  • 12个月免于靶病变血运重建率支架组为80.9%(95%CI 73.3%至88.5%),旁路组为76.2%(95%CI 68.0%至84.4%),p=0.471。
  • 30天并发症率支架组为4.4%,旁路组为11.3%,p=0.004。
  • 支架组手术时间和住院时间均显著短于旁路组(p<0.001)。

关键数值与推荐

  • 主要终点12个月一期通畅率定义为:双功超声峰值收缩速度比<2.4且无临床驱动的靶病变血运重建(支架组)或无需再干预恢复血流(旁路组)。

临床怎么用

  • 对于长段TASC C和D股腘动脉病变,可考虑将ZILVER PTX紫杉醇洗脱支架作为旁路手术的替代选择,尤其适合希望降低围手术期并发症和缩短住院时间的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To report the 12-month results of a multicenter, prospective, randomized controlled trial to determine if the ZILVER PTX paclitaxel-eluting stent was noninferior in terms of safety and efficacy compared with surgical bypass. Materials and Methods: This is a study in symptomatic TransAtlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions comparing endovascular ZILVER PTX stenting vs surgical bypass surgery using a prosthetic graft (ClinicalTrials.gov identifier NCT01952457). Between October 2013 and July 2017, 220 patients (mean age 68.6±10.5 years; 159 men) were enrolled and randomized to the ZILVER PTX treatment group (113, 51.4%) or the bypass treatment group (107, 48.6%). Most of the lesions were occlusions (208, 94.5%); the mean lesion length was 247.1±69.3 mm. The primary outcome measure was primary patency at 12 months, defined as no evidence of binary restenosis or occlusion within the target lesion or bypass graft based on a duplex-derived peak systolic velocity ratio <2.4 and no clinically-driven target lesion revascularization (TLR) in endovascular cases or reintervention to restore flow in the bypass. Results: The estimated 12-month primary patency rate was 74.5% (95% CI 66.3% to 82.7%) for the ZILVER PTX group vs 72.5% (95% CI 63.7% to 81.3%) for the bypass arm (p=0.998). Freedom from TLR at 12 months was 80.9% (95% CI 73.3% to 88.5%) for the ZILVER PTX group vs 76.2% (95% CI 68.0% to 84.4%) for the bypass group (p=0.471). The 30-day complication rate was significantly lower in the ZILVER PTX group (4.4% vs 11.3%, p=0.004). Also, procedure time and hospital stay were significantly shorter in the ZILVER PTX group (p<0.001 for both). Conclusion: With noninferior patency results, a lower complication rate, and shorter procedures and hospital stays, paclitaxel-eluting stenting might become a recommended treatment for long TASC C and D femoropopliteal lesions.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bosiers M, Setacci C, De Donato G, et al. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions. J Endovasc Ther. 2020. PMID: 31997715. doi:10.1177/1526602820902014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。